COHR enters the week in an uncomfortable spot — the stock is down 10% in five days and 17% over the past month, while short sellers are rebuilding positions at a pace that stands out even against a tough tape.
The short interest story is the sharpest signal this week. Bearish positioning has jumped 30% in just five trading sessions, pushing SI to roughly 6.7% of the free float — a meaningful and rising level. That acceleration started around September 9, when shares outstanding short climbed from 8.7 million to over 10.5 million by week's end. The move is not being amplified by a tight borrow market, however. Availability remains very loose at roughly 1,138% — meaning there are more than eleven shares available to borrow for every one already lent out — and the cost to borrow, at 0.48%, is barely above zero. Shorts are adding with no friction. That's a build driven by conviction, not a mechanical squeeze of existing positions. The ORTEX short score has drifted up to 39.5 from 35.1 a week ago, reflecting the accumulation, though it remains in moderate territory relative to the broader universe.
Options positioning corroborates the caution. The put/call ratio is running at 1.28, just a touch above its 20-day average of 1.26 — not an extreme reading, but consistently elevated. The ratio has held above 1.20 for the bulk of the past month, and it briefly hit 1.34 in late August. This isn't panic hedging; it's a steady, persistent lean toward downside protection that has been in place for weeks. Closest peers confirm the sector is under pressure broadly: fell 13.5% on the week, dropped 13.1%, and shed nearly 10% — suggesting macro or sector-level selling rather than anything uniquely COHR-specific.
The Street, for its part, is holding the line. The analyst consensus remains a buy, and the wave of post-earnings target increases in mid-August — Jefferies lifting to $420, Needham to $420, and Rosenblatt all the way to $500 — left the mean price target at $415. Deutsche Bank initiated coverage at the start of September with a $400 buy target. At the current price of $271, that gap implies roughly 50% upside by Street math, which is a wide spread that reflects genuine disagreement between analysts and the market right now. Morgan Stanley, sitting at Equal-Weight with a $375 target, is the most prominent voice in the cautious camp. Factor scores add texture: EPS momentum ranks in the 96th percentile over 90 days, and the analyst recommendation differential ranks in the 98th percentile — the Street has rarely been this constructive relative to the stock's history. But the EV/EBIT rank sits near the bottom of the universe at the 13th percentile, flagging the valuation stretch the bears keep pointing to.
One detail on the ownership register worth noting: BCPE Watson, which filed a Schedule 13D activist position — the most significant filing type, indicating intent to engage management — last disclosed a 5.2% stake and has filed five times since November 2025. Their most recent amendment was in February 2026, and the current percent of class is unreported in the latest filing, meaning the position may have changed. Per standard disclosure rules, stakes are as-last-reported around the 5% threshold, and a holder who drops below 5% need not file again. On the insider side, the 90-day net is a $8.5 million disposal across multiple executives, with Director Enrico Digirolomo's $1.6 million open-market sale on September 11 notable for being a discretionary transaction — not covered by a 10b5-1 plan. The CTO's sales were pre-planned. The mix of discretionary and planned selling doesn't tell a single clean story, but the absence of any open-market buying is a quiet signal.
With the next earnings event pencilled in for November 6, the period ahead is defined by this gap between a strongly bullish sell-side and a market that has spent a month voting the other way — the question framing that print is whether COHR's AI infrastructure demand narrative can close that spread.
See the live data behind this article on ORTEX.
Open COHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
